FDA removes black-box warnings from three menopause treatment patches

• The FDA removed black-box warnings from three estrogen patches for treating menopause.
• The decision was made without convening an advisory committee, raising concerns about transparency.
• The removed warnings pertained to cardiovascular disease, breast cancer, and dementia.
• Some experts have expressed concern about the lack of transparency in the FDA's decision.
• This move follows a broader policy shift to reverse nearly two decades of stigma around hormone replacement therapies.